BACKGROUND: Several recent trials indicate positive effects of psilocybin in patients with major depressive disorder. However, questions need to be addressed regarding the relationship between dosage and therapeutic outcomes, such as the recommended dose range and frequency for optimal practice as well as the dose-dependent adverse effects. OBJECTIVE: (1) to assess the effectiveness and...
The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a...
Esketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic side effects related to dextromethorphan metabolites, and seizure risks associated with high-dose bupropion....